SEC Form 4 · accession 0002044770-26-000006
Tarsus Pharmaceuticals, Inc. · TARS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Katherine Goodrich
Director
Period of report
Jun 15, 2026
Accepted (ET)
Jun 17, 2026 · 4:17 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001819790
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 15, 2026 | S | 2,954 | $62.08 | D | 2,233 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.